AROA BIOSURGERY LTD(ARX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

ARX.AU AROA BIOSURGERY LTD

Not Yet Opened 01-09 16:12:00 AEDT

0.80

+0.00

0.00%

High0.82	Low0.78	Vol195.72K
Open0.80	D1 Closing0.80	Amplitude5.00%
Mkt Cap275.92M	Tradable Cap207.58M	Total Shares344.90M
T/O155.59K	T/O Rate0.08%	Tradable Shares259.47M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ARX.AU","market":"AU","secType":"STK","nameCN":"AROA BIOSURGERY LTD","latestPrice":0.8,"timestamp":1736399520000,"preClose":0.8,"halted":0,"volume":195722,"delay":0,"nameEN":"AROA BIOSURGERY LTD","floatShares":259472084,"shares":344900256,"eps":-0.019953230830277974,"marketStatus":"Not Yet Opened","change":0,"latestTime":"01-09 16:12:00 AEDT","open":0.8,"high":0.815,"low":0.775,"amount":155594,"amplitude":0.05,"askPrice":0.8,"askSize":2000,"bidPrice":0.785,"bidSize":7782,"shortable":3,"etf":0,"ttmEps":-0.019953230830277974,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1736463600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.8,"openAndCloseTimeList":[[1736377200000,1736398800000]],"volumeRatio":0.467514,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/ARX.AU","defaultTab":"news","newsList":[{"id":"2493135277","title":"Aroa Biosurgery Says Real-World Study Backs Efficacy of Regenerative Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2493135277","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493135277?lang=en_us&edition=fundamental","pubTime":"2024-12-23 09:50","pubTimestamp":1734918617,"startTime":"0","endTime":"0","summary":"Aroa Biosurgery  said a real-world study showed the efficacy of its Myriad product designed for limb reconstruction procedures, according to a Monday filing with the Australian bourse.The study, conducted in patients with high risks of complications and amputations, showed that the Myriad Matrix and Myriad Morcells regenerative products were able to achieve full coverage with no infections and complications, the filing said.The study covered 120 patients with 130 lower limb defects, the filing said. Across all participants, 95% had at least one risk factor for amputation, and 55% had three or more risk factors.Results were published in the peer-reviewed journal Plastic and Reconstructive Surgery - Global Open.The company's shares gained close to 2% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2492997217","title":"Insiders own 25% of Aroa Biosurgery Limited (ASX:ARX) shares but individual investors control 51% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2492997217","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492997217?lang=en_us&edition=fundamental","pubTime":"2024-12-18 04:03","pubTimestamp":1734465797,"startTime":"0","endTime":"0","summary":"The considerable ownership by individual investors in Aroa Biosurgery indicates that they collectively have a greater say in management and business strategy. To get a sense of who is truly in control of Aroa Biosurgery Limited , it is important to understand the ownership structure of the business. We can see that individual investors own the lion's share in the company with 51% ownership. That is, the group stands to benefit the most if the stock rises .And individual insiders on the other hand have a 25% ownership in the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies.Let's take a closer look to see what the different types of shareholders can tell us about Aroa Biosurgery.ASX:ARX Earnings and Revenue Growth December 17th 2024. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the ve","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insiders-own-25-aroa-biosurgery-200317009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2489238021","title":"Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489238021","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489238021?lang=en_us&edition=fundamental","pubTime":"2024-12-05 04:01","pubTimestamp":1733342463,"startTime":"0","endTime":"0","summary":"Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/aroa-biosurgery-limited-asxarx-held-back-by-insufficient-gro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2486359290","title":"The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2486359290","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486359290?lang=en_us&edition=fundamental","pubTime":"2024-11-28 07:31","pubTimestamp":1732750305,"startTime":"0","endTime":"0","summary":"It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/the-aroa-biosurgery-limited-asxarx-interim-results-are-out-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2486856028","title":"ASX Penny Stocks To Watch In November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2486856028","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486856028?lang=en_us&edition=fundamental","pubTime":"2024-11-27 07:07","pubTimestamp":1732662458,"startTime":"0","endTime":"0","summary":"The Australian market is showing resilience, with the ASX 200 expected to gain despite global economic uncertainties, such as newly proposed tariffs and geopolitical tensions. In this context, investors might find interest in penny stocks—typically smaller or newer companies that offer a blend of affordability and growth potential. While the term \"penny stocks\" may seem outdated, these investments can still present compelling opportunities when they exhibit strong financials and solid fundamentals.Overview: Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix technology in the United States and internationally, with a market cap of A$231.08 million.Impact Minerals, with a market cap of A$39.77 million, remains pre-revenue, reporting minimal sales of A$0.12 million and a net loss","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CgF_bHzIPDCsG3KwCCLvew--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2bc7e9c938f83604e86f7ffd61b40d2a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CgF_bHzIPDCsG3KwCCLvew--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2bc7e9c938f83604e86f7ffd61b40d2a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-penny-stocks-watch-november-230738990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPT.AU","NVX","NVX.AU","BK4157","ARX.AU"],"gpt_icon":0},{"id":"2486168856","title":"2 small cap ASX stocks with big price targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2486168856","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486168856?lang=en_us&edition=fundamental","pubTime":"2024-11-27 05:20","pubTimestamp":1732656058,"startTime":"0","endTime":"0","summary":"If you have a higher than average tolerance for risk, then it could be worth considering a few small cap ASX stocks for a balanced portfolio. That's because the potential returns on offer at the small","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/27/2-small-cap-asx-stocks-with-big-price-targets/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4209","BK7067","ARX.AU","PC","CHL.AU","BK7161"],"gpt_icon":0},{"id":"2486533060","title":"BUZZ-ASX-listed Aroa Biosurgery rises as H1 loss narrows, upbeat H2 outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2486533060","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486533060?lang=en_us&edition=fundamental","pubTime":"2024-11-26 07:52","pubTimestamp":1732578754,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Aroa Biosurgery rises as H1 loss narrows, upbeat H2 outlook** Shares of Aroa Biosurgery ARX.AX rise as much as 3.85% to A$0.675, their highest level since Nov. 13** NZ's medical products maker posts H1 FY25 loss after tax attributable of NZ$3.3 mln , compared to NZ$6.3 mln from a year before** H1 FY25 revenue from ordinary activities - product sales NZ$39.1 mln, up 25% from a year before** Co anticipates H2 FY25 total revenue of NZ$43-$50 million** Expects H2 FY25 normalised EBITDA profit of NZ$4-8 mln** However stock has fallen 21.7% YTD, as of last close  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nL3N3MW136:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2486065532","title":"BRIEF-Aroa Biosurgery Anticipates H2 FY25 Total Revenue Of NZ$43-$50 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2486065532","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486065532?lang=en_us&edition=fundamental","pubTime":"2024-11-26 05:49","pubTimestamp":1732571347,"startTime":"0","endTime":"0","summary":"BRIEF-Aroa Biosurgery Anticipates H2 FY25 Total Revenue Of NZ$43-$50 MillionNov 26  - Aroa Biosurgery Ltd ARX.AX:ANTICIPATES H2 FY25 TOTAL REVENUE OF NZ$43-$50 MILLIONEXPECTS H2 FY24 NORMALISED EBITDA PROFIT OF NZ$4-8 MLNFurther company coverage: ARX.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nFWN3MW0R4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX.AU"],"gpt_icon":0},{"id":"2486065334","title":"BRIEF-Aroa Biosurgery Posts H1 Product Revenue NZ$39.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2486065334","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486065334?lang=en_us&edition=fundamental","pubTime":"2024-11-26 05:43","pubTimestamp":1732571018,"startTime":"0","endTime":"0","summary":"Nov 26  - Aroa Biosurgery H1 product revenue NZD 39.1 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nPLX4F36FD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX.AU"],"gpt_icon":0},{"id":"2486306379","title":"Aroa Biosurgery Ltd -  Anticipates H2 FY25 Total Revenue of Nz$43-$50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2486306379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486306379?lang=en_us&edition=fundamental","pubTime":"2024-11-26 05:39","pubTimestamp":1732570796,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nFWN3MW0R4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2486063257","title":"Aroa Biosurgery H1 Product Revenue Nzd 39.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2486063257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486063257?lang=en_us&edition=fundamental","pubTime":"2024-11-26 05:39","pubTimestamp":1732570745,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nPLX4F36FD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2483017211","title":"We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn","url":"https://stock-news.laohu8.com/highlight/detail?id=2483017211","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483017211?lang=en_us&edition=fundamental","pubTime":"2024-11-13 08:35","pubTimestamp":1731458102,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/were-not-worried-about-aroa-biosurgerys-asxarx-cash-burn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARX.AU","BK7067"],"gpt_icon":1},{"id":"2482260762","title":"Aroa Biosurgery Limited (ASX:ARX): Is Breakeven Near?","url":"https://stock-news.laohu8.com/highlight/detail?id=2482260762","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482260762?lang=en_us&edition=fundamental","pubTime":"2024-11-12 06:32","pubTimestamp":1731364375,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse Aroa Biosurgery Limited's  business as it appears the company may be on the cusp of a considerable accomplishment. Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix  technology in the United States and internationally. The AU$224m market-cap company announced a latest loss of NZ$11m on 31 March 2024 for its most recent financial year result. As path to profitability is the topic on Aroa Biosurgery's investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Aroa Biosurgery’s board and the CEO’s background.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aroa-biosurgery-limited-asx-arx-223255191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2477774178","title":"Aroa Biosurgery Wins Regulatory Approvals for Wound Care Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2477774178","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477774178?lang=en_us&edition=fundamental","pubTime":"2024-10-22 14:46","pubTimestamp":1729579583,"startTime":"0","endTime":"0","summary":"Aroa Biosurgery's  secured regulatory approvals to market and sell the Endoform and Myriad Matrix products in Argentina and Endoform in Egypt, according to a Tuesday filing with the Australian bourse.Endoform was developed for the management of acute and chronic wounds, while Myriad Matrix is used in soft tissue reconstruction and complex wounds.The soft tissue regeneration firm's cash receipts rose 35% to NZ$19.9 million in the second quarter ended Sept. 30, compared with the previous comparable period, the filing added.Shares of Aroa Biosurgery rallied almost 12% at market close.Price : $0.58, Change: $+0.060, Percent Change: +11.54%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4125","BK7067","ARX.AU","AUD"],"gpt_icon":0},{"id":"2477820035","title":"BUZZ-ASX-listed Aroa Biosurgery hits over 10-week high on FY outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2477820035","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477820035?lang=en_us&edition=fundamental","pubTime":"2024-10-22 11:45","pubTimestamp":1729568736,"startTime":"0","endTime":"0","summary":"** ASX-listed shares of Aroa Biosurgery    rise as much as 15.4% to A$0.6, their highest since Aug. 12   ** NZ's Medical products maker expects to be operating cash flow positive in the second half of FY25   ** Co says FY25 normalised EBITDA guidance maintained at NZ$2 mln  to NZ$6 mln   ** Says, FY25 revenue guidance maintained between NZ$80 mln and NZ$87 mln   ** ARX to release financial results for H1 FY25 on Nov. 26   ** Stock down 30.7% YTD  ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2477784205","title":"BRIEF-Aroa Biosurgery Maintains FY25 Revenue Guidance At NZ$80-87 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2477784205","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477784205?lang=en_us&edition=fundamental","pubTime":"2024-10-22 08:40","pubTimestamp":1729557622,"startTime":"0","endTime":"0","summary":"Oct 22 (Reuters) - Aroa Biosurgery Ltd   :   * FY25 REVENUE GUIDANCE MAINTAINED AT NZ$80-87 MILLION   * FY25 NORMALISED EBITDA PROFIT GUIDANCE MAINTAINED AT NZ$2-6 MILLION Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX.AU"],"gpt_icon":0},{"id":"2477817591","title":"Aroa Biosurgery Ltd -  FY25 Normalised Ebitda Profit Guidance Maintained at Nz$2-6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2477817591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477817591?lang=en_us&edition=fundamental","pubTime":"2024-10-22 05:44","pubTimestamp":1729547045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nFWN3LX19C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2473118355","title":"Insider Buys Additional NZ$150k In Aroa Biosurgery Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2473118355","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473118355?lang=en_us&edition=fundamental","pubTime":"2024-10-07 06:52","pubTimestamp":1728255123,"startTime":"0","endTime":"0","summary":"Potential Aroa Biosurgery Limited  shareholders may wish to note that the Independent Non-Executive Director, Catherine Mohr, recently bought AU$150k worth of stock, paying AU$0.34 for each share. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.Aroa Biosurgery Insider Transactions Over The Last Year. Over the last year, we can see that the biggest insider purchase was by Non-Executive Director Philip McCaw for AU$176k worth of shares, at about AU$0.54 per share. That means that an insider was happy to buy shares at above the current price of AU$0.53. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.If you would prefer to check out another company -- one with potenti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-buys-additional-nz-150k-225203755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ARX.AU","BK7067"],"gpt_icon":0},{"id":"2470474756","title":"Aroa Biosurgery Limited (ASX:ARX): When Will It Breakeven?","url":"https://stock-news.laohu8.com/highlight/detail?id=2470474756","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470474756?lang=en_us&edition=fundamental","pubTime":"2024-09-25 04:12","pubTimestamp":1727208760,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Aroa Biosurgery...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/aroa-biosurgery-limited-asxarx-when-will-it-breakeven","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","ARX.AU"],"gpt_icon":0},{"id":"2465853676","title":"Experts name 2 small cap ASX stocks to buy for big returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2465853676","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465853676?lang=en_us&edition=fundamental","pubTime":"2024-09-06 08:10","pubTimestamp":1725581427,"startTime":"0","endTime":"0","summary":"Given the strong potential returns on offer at the small end of the market, it could be worth adding a few small cap ASX stocks to a balanced investment portfolio if you have a high risk tolerance. But which small caps could be top options for investors in September?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/09/06/experts-name-2-small-cap-asx-stocks-to-buy-for-big-returns/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PC","BK7067","ARX.AU","CHL.AU","BK7161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://aroabio.com","stockEarnings":[{"period":"1week","weight":0.0738},{"period":"1month","weight":0.2121},{"period":"3month","weight":0.4815},{"period":"6month","weight":0.2903},{"period":"1year","weight":0.0063},{"period":"ytd","weight":0.039}],"compareEarnings":[{"period":"1week","weight":-0.0032},{"period":"1month","weight":-0.0109},{"period":"3month","weight":0.0239},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1607},{"period":"ytd","weight":0.0034}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Aroa Biosurgery Limited designs and manufactures medical products, which enable surgeons and clinicians to repair serious tissue injuries. It offers Endoform, a high performance building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing; Endoform Dermal Template, an intact extracellular matrix to treat acute and chronic wounds from day one; and Reinforced Bioscaffolds, a surgical product that is primarily designed for use in ventral hernia repair and abdominal wall reconstruction. The company's products are distributed through medical technology companies. Aroa Biosurgery Limited was formerly known as Mesynthes Ltd. and changed its name to Aroa Biosurgery Limited in June 2015. The company was founded in 2007 and is based in Auckland, New Zealand.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.027042},{"month":2,"riseRate":0.25,"avgChangeRate":-0.013342},{"month":3,"riseRate":0.25,"avgChangeRate":0.009197},{"month":4,"riseRate":0.25,"avgChangeRate":-0.02293},{"month":5,"riseRate":0.25,"avgChangeRate":-0.043353},{"month":6,"riseRate":0.75,"avgChangeRate":0.0884},{"month":7,"riseRate":0,"avgChangeRate":-0.096942},{"month":8,"riseRate":0.4,"avgChangeRate":-0.008858},{"month":9,"riseRate":0.6,"avgChangeRate":0.051819},{"month":10,"riseRate":0.6,"avgChangeRate":0.066178},{"month":11,"riseRate":0.6,"avgChangeRate":0.005181},{"month":12,"riseRate":0.4,"avgChangeRate":-0.073403}],"exchange":"ASX","name":"AROA BIOSURGERY LTD","nameEN":"AROA BIOSURGERY LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AROA BIOSURGERY LTD(ARX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AROA BIOSURGERY LTD(ARX.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AROA BIOSURGERY LTD,ARX.AU,AROA BIOSURGERY LTD股票,AROA BIOSURGERY LTD股票老虎,AROA BIOSURGERY LTD股票老虎国际,AROA BIOSURGERY LTD行情,AROA BIOSURGERY LTD股票行情,AROA BIOSURGERY LTD股价,AROA BIOSURGERY LTD股市,AROA BIOSURGERY LTD股票价格,AROA BIOSURGERY LTD股票交易,AROA BIOSURGERY LTD股票购买,AROA BIOSURGERY LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AROA BIOSURGERY LTD(ARX.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AROA BIOSURGERY LTD(ARX.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction